

ReNeuron Group

Global clinical pipeline strategy update

Clinical pipeline update

Pharma & biotech

ReNeuron continues to prepare for its Phase III chronic stroke study (due to start in H217) and has indicated that it is making progress with the US/EU regulatory authorities. It intends to submit an IND in the US in Q217 and shortly after in the EU. ReNeuron also announced that it now plans to expand its ongoing Phase I/II retinitis pigmentosa (hRP cells) study to 20 patients in Phase II and commence a Phase II study in a new indication: cone-rod dystrophy (CRD). As a result, it will not continue development of CTX in critical limb ischaemia (CLI). We maintain our rNPV at £291m.

Year end	Revenue (£m)	PBT* (£m)	EPS* (p)	DPS (p)	P/E (x)	Yield (%)
03/15	0.0	(10.3)	(0.50)	0.0	N/A	N/A
03/16	0.0	(12.8)	(0.44)	0.0	N/A	N/A
03/17e	0.0	(19.5)	(0.58)	0.0	N/A	N/A
03/18e	0.0	(31.3)	(0.93)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Phase III chronic stroke study set-up progressing

ReNeuron reported positive Phase II trial data (December 2016) for its CTX cells in chronic stroke patients. It has recently announced that it is on track to initiate the follow-on Phase III trial in H217. It is currently consulting with the regulatory bodies in Europe and the US, has an end-of-Phase II meeting with the FDA shortly and intends to submit an IND in Q217. The European clinical trial application will follow shortly after. Alongside this, discussions are ongoing with the Japanese regulatory agency, which could offer a conditional marketing approval. For more detail, see our March 2017 [outlook note](#).

Ophthalmology clinical programme expanded

ReNeuron also recently announced the expansion of its ophthalmology programme, following successful development of a cryopreserved formulation of its hRP cells. It intends to expand the Phase II part of the trial in RP patients (20 patients vs six patients) to utilise the cryopreserved hRPCs and build a richer data set. We expect efficacy data readouts to now be in H218. Alongside this, it is also expanding development of hRPCs into CRD, with a Phase II trial application planned in H217. As a result of the expansion of its clinical programme, the CLI programme is on hold. A Phase I safety study in CLI has been completed with no significant adverse events, according to the company.

Valuation: Maintained at £291m, positive progress

We maintain our valuation at £291m. We have removed the CLI programme from the valuation, but this has been tempered by the inclusion of the CRD programme, an increase in the assumption of the price of hRP cell treatment and an updated £/\$ conversion of 1.28 (vs 1.32). We believe ReNeuron is making positive developments by focusing on its clinical programme. There are a number of potential inflection points as it executes its strategy. We currently forecast a cash runway into FY19, which should enable significant advancement of its clinical programmes. At that point, it will either raise further funding and/or partner some of its programmes.

2 May 2017

Price **2.20p**

Market cap **£70m**

£/\$ 1.28

Net cash (£m) at 30 September 2016 60.0

Shares in issue 3,164.6m


Free float 60.5%

Code RENE

Primary exchange AIM

Secondary exchange N/A

Share price performance



% 1m 3m 12m

Abs 1.2 (14.6) (32.3)

Rel (local) (5.6) (11.7) (38.4)

52-week high/low 3.7p 2.1p

Business description

ReNeuron is a UK biotech company developing allogeneic cell therapies. CTX neural stem cells are in development for ischaemic stroke disability (Phase III planned) and critical limb ischaemia (Phase I), and human retinal progenitor cells (hRPCs) are being studied for retinitis pigmentosa (Phase I/II).

Next events

IND filing with FDA for Phase III stroke trial H117

Initiation of Phase III stroke trial H217

hRPC: safety data H217

12-month follow-up from PISCES II stroke trial H217

Analyst

Dr Linda Pomeroy +44 (0)20 3077 5738

healthcare@edisongroup.com

[Edison profile page](#)

ReNeuron Group is a research client of Edison Investment Research Limited

Updated clinical pipeline overview

ReNeuron has a broad clinical pipeline with multiple data readouts anticipated in the next couple of years. For a full company overview, please see our [outlook note](#) published on 23 March 2017.

Expanded ophthalmology programmes

ReNeuron has announced that it has successfully developed a cryopreserved formulation of its human retinal progenitor cell (hRPC) therapeutic candidate. This is a significant step forward as it enables shipping and storage, increasing the shelf life of the product and enabling potentially far-reaching commercialisation. This has enabled ReNeuron to apply to alter its current US Phase I/II clinical trial to switch from a fresh hRPC formulation for the final Phase I dose cohort (three patients). Alongside this it has allowed an expansion of its programme in ophthalmology. It intends to apply to extend the Phase II element of the ongoing Phase I/II clinical trial in RP to 20 patients (vs six patients) and expand it to a new indication: cone-rod dystrophy (CRD).

hRPC to be pursued in two indications

hRPC is currently being investigated in a Phase I/II study in retinitis pigmentosa (RP), in which the Phase I part is progressing as planned and the Phase II part is expected to be expanded to include 20 patients across additional US clinical study sites. The Phase I trial has three dose cohorts with three patients in each and currently two of the three safety dose cohorts have completed. The study is being conducted at the Massachusetts Eye and Ear Infirmary (Boston) and is the first clinical trial activity in the US for ReNeuron. Please see our July 2016 [outlook note](#) for a more detailed overview of RP and an outline of the trial design.

hRPC has received both fast-track designation (accelerated approval and priority review) and orphan drug status for RP in the US, and orphan drug status in Europe, thus ensuring seven and 10 years of market exclusivity, respectively, following any approval. Initial safety readouts are expected in H117, with efficacy data now expected later due to the additional patients in H218.

ReNeuron has announced its intention to expand the hRPC retinal disease programme into CRD. CRD is a group of rare eye disorders associated with the loss of cone cells in the retina that initially results in deterioration of central visual acuity (frequency 5-29%¹) and colour vision (frequency 30-79%¹). It is an inherited orphan disease (one in 40,000 people²) and generally starts in childhood, with no cure currently. The expansion to include a second indication is part of ReNeuron's strategy to evaluate the efficacy of its hRPC therapeutic candidate across a range of genetic diseases of the eye. It intends to file an application to commence a Phase II study H217.

Phase III chronic stroke study – H217

ReNeuron has indicated that the rate of patient improvement as measured in the Phase II study (motor scales, global impairment and activities of daily living independence) exceeded what it expected would be due to natural recovery alone. As a result, ReNeuron is planning to progress clinical development of its CTX cell therapy candidate in patients with disability due to ischaemic stroke in a Phase III pivotal, controlled, randomised study. We expect this to take place predominantly in the US, with possibly a few sites in Europe and, while it is too early to state what the primary endpoints may be, we do expect it to utilise the scales already outlined here in Phase II, albeit potentially with a different emphasis. In particular, we expect a focus on measures of disability and daily living such as BI and mRS, as these are particularly favoured by regulators. ReNeuron has met with the EU regulators and will be meeting with the US regulators shortly. It expects to file

¹ <https://rarediseases.info.nih.gov/diseases/10790/cone-rod-dystrophy>

² <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808442/>

an IND in the US in Q217 and shortly after in Europe. We believe there is potential readout from the trial in 2019. In addition to its progress in the US and Europe, ReNeuron is continuing to move forward in Japan, where it has also met with the regulatory agency (PDMA). The Japanese market offers an interesting opportunity as there are regulations that offer the potential for conditional marketing approval at an earlier stage of clinical development. We expect ReNeuron to find a partner to commercialise in Japan. For a more detailed overview of Phase II clinical stroke study data, see our March 2017 [outlook note](#).

Exosome nanomedicine platform potentially in clinic H118

ReNeuron is currently engaged in preclinical work around its exosome platform. If the outcome of the preclinical work is positive, the company intends to start a Phase I clinical trial in H118. We expect this could be granted orphan indication status if successful, which has the benefit of market exclusivity post-launch. There is also the potential for ReNeuron to partner with this programme, as exosomes could be a target vehicle for drug delivery. To view published data click [here](#) and for a more detailed overview of the programme, please see our July 2016 [outlook note](#).

Valuation: Maintained at £291m

We are maintaining our valuation at £291m. We have removed the CLI programme from our valuation, which has been offset by the inclusion of the CRD programme, an increase in the price of the hRPC treatment to \$75,000 per treatment vs \$50,000 previously and using an updated £/\$ conversion of 1.28 (vs 1.32 before). We also now use our estimated FY17 cash of £44m (vs H117 reported cash of £60m). Exhibit 1 outlines our key assumptions around the CRD programme. Our assumptions for the other programmes remain the same. We noted in our previous report that pricing of \$50k per eye treatment (RP and CRD programme) is conservative as a transformational disease-modifying treatment. We have reviewed this in our model, as stated above, but still believe it could be priced higher. We also note that we do not currently ascribe value to its exosome programme.

Exhibit 1: rNPV valuation and assumptions

Product	Setting	Status	Launch	NPV (£m)	Peak sales (\$m)	Probability of success	Royalty rate	rNPV (£m)	rNPV per share (p)	Key assumptions
CTX	Stroke disability	Phase II completed	2020	765	1,633	25%	30%	175	5.54	1.76m strokes/yr (US 800k + EU 800k + Japan 155k); 85% ischaemic; 85% survival; 50% disability; 10% peak penetration; treatment cost \$50,000 (US/Japan) or \$40,000 (EU).
hRPC	CRD	Phase II ready	2020	94	147	20%	30%	14	0.45	CRD prevalence 1 in 40,000; 30% advance to severe vision loss per year and abnormal colour vision ; peak penetration 20% (US/Japan) or 15% (EU); per-eye treatment cost \$75,000 (US/Japan) or \$50,000 (EU).
hRPC	RP	Phase I/II	2020	331	629	20%	30%	57	1.80	RP prevalence 1 in 4,000; 10% advance to severe vision loss per year; peak penetration 20% (US/Japan) or 15% (EU); per-eye treatment cost \$75,000 (US/Japan) or \$50,000 (EU).
Portfolio total				1,190				246	7.79	
Cash								44	1.40	FY17 estimated cash
Overall valuation								291	9.19	3,164m shares outstanding

Source: Edison Investment Research

We maintain our forecasts, as overall we expect the same spend as before the change in clinical programme mix. ReNeuron has a strong cash position (we forecast a cash runway to FY19), which should allow the company to significantly advance its clinical trial programme, resulting in a number of potential key inflection points over the next 24 months, including:

- initiation of a pivotal Phase III study for CTX in stroke (H217);
- Phase I hRPC safety data in 2017;
- initiation of Phase II hRPC study in RP and CRD; and
- further preclinical data from the exosome nanomedicine platform (efficacy and toxicity).

Exhibit 2: Financial summary

	£'000s	2013	2014	2015	2016	2017e	2018e
Year end 31 March		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS							
Revenue		17	22	30	29	29	29
Cost of Sales		0	0	0	0	0	0
Gross Profit		17	22	30	29	29	29
R&D expenses		(4,786)	(5,829)	(7,250)	(10,272)	(16,435)	(27,940)
SG&A expenses		(2,319)	(2,824)	(3,693)	(4,015)	(4,095)	(4,300)
EBITDA		(6,966)	(7,857)	(10,269)	(13,632)	(19,895)	(31,549)
Operating Profit (before GW and except)		(7,088)	(7,969)	(10,394)	(13,724)	(19,968)	(31,677)
Intangible Amortisation		0	0	0	0	0	0
Exceptionals		0	0	0	0	0	0
Operating Profit		(7,088)	(7,969)	(10,394)	(13,724)	(19,968)	(31,677)
Other		0	0	0	0	0	0
Net Interest		29	149	91	878	493	371
Profit Before Tax (norm)		(7,059)	(7,820)	(10,303)	(12,846)	(19,475)	(31,306)
Profit Before Tax (FRS 3)		(7,059)	(7,820)	(10,303)	(12,846)	(19,475)	(31,306)
Tax		714	754	1,397	1,492	1,168	1,878
Profit After Tax (norm)		(6,345)	(7,066)	(8,906)	(11,354)	(18,306)	(29,428)
Profit After Tax (FRS 3)		(6,345)	(7,066)	(8,906)	(11,354)	(18,306)	(29,428)
Average Number of Shares Outstanding (m)		748.7	1,425.0	1,788.8	2,609.3	3,164.6	3,164.6
EPS - normalised (p)		(0.85)	(0.50)	(0.50)	(0.44)	(0.58)	(0.93)
EPS - FRS 3 (p)		(0.85)	(0.50)	(0.50)	(0.44)	(0.58)	(0.93)
Dividend per share (p)		0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET							
Fixed Assets		1,620	1,772	2,033	6,963	7,242	8,872
Intangible Assets		1,272	1,272	1,591	1,591	1,591	1,591
Tangible Assets		213	225	161	361	640	2,270
Other		135	275	281	5,011	5,011	5,011
Current Assets		4,602	22,347	14,054	64,894	47,003	16,654
Stocks		0	0	0	0	0	0
Debtors		341	676	400	1,421	1,421	1,421
Cash		3,547	20,917	12,382	60,709	44,413	13,354
Other		714	754	1,272	2,764	1,168	1,878
Current Liabilities		(1,164)	(2,036)	(2,345)	(4,199)	(4,199)	(4,199)
Creditors		(539)	(1,234)	(1,150)	(3,700)	(3,700)	(3,700)
Short term borrowings		0	0	0	0	0	0
Short term leases		(1)	(1)	(1)	(1)	(1)	(1)
Other		(624)	(801)	(1,194)	(498)	(498)	(498)
Long Term Liabilities		(150)	(366)	(606)	0	0	0
Long term borrowings		0	0	0	0	0	0
Long term leases		0	(2)	(1)	0	0	0
Other long term liabilities		(150)	(364)	(605)	0	0	0
Net Assets		4,908	21,717	13,136	67,658	50,046	21,327
CASH FLOW							
Operating Cash Flow		(6,637)	(6,718)	(9,124)	(11,920)	(19,201)	(30,840)
Net Interest		(1)	0	0	0	0	0
Tax		616	714	879	0	2,764	1,168
Capex		(37)	(121)	(380)	(293)	(352)	(1,758)
Acquisitions/disposals		0	0	0	0	0	0
Financing		5,601	23,435	0	65,195	0	0
Dividends		0	0	0	0	0	0
Other		30	61	91	345	493	371
Net Cash Flow		(428)	17,371	(8,534)	53,327	(16,295)	(31,059)
Opening net debt/(cash)		(3,974)	(3,546)	(20,914)	(12,380)	(65,708)	(49,413)
HP finance leases initiated		0	(3)	0	1	0	0
Other		0	0	0	(0)	0	0
Closing net debt/(cash)		(3,546)	(20,914)	(12,380)	(65,708)	(49,413)	(18,353)

Source: ReNeuron accounts, Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by ReNeuron Group and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.